Which has stronger earnings and valuation, EVO or IKT?

Inhibikase Therapeutics has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.85 -$117.12M N/A N/A Inhibikase Therapeutics $260K 1,046.08 -$48.26M -$0.43 N/A

Does the media refer more to EVO or IKT?

In the previous week, Evotec and Evotec both had 8 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Evotec's score of 0.20 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ETON or IKT?

In the previous week, Inhibikase Therapeutics had 6 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 2 mentions for Eton Pharmaceuticals. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Eton Pharmaceuticals' score of 0.97 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IKT or AVTX more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Avalo Therapeutics N/A -97.54% -72.42%

Does the media prefer IKT or AVTX?

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Avalo Therapeutics. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 3 mentions for Avalo Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Avalo Therapeutics' score of 0.65 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IKT or KURA?

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 8 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Kura Oncology's score of 1.07 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibikase Therapeutics (IKT) Competitors

$2.06 +0.10 (+5.10%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.02 -0.04 (-1.75%)

As of 07/14/2026 07:50 PM Eastern

Compare

IKT vs. CVAC, EVO, ETON, AVTX, and KURA

Should you buy Inhibikase Therapeutics stock or one of its competitors? MarketBeat compares Inhibikase Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibikase Therapeutics include CureVac (CVAC), Evotec (EVO), Eton Pharmaceuticals (ETON), Avalo Therapeutics (AVTX), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.

How does Inhibikase Therapeutics compare to CureVac?

Inhibikase Therapeutics (NASDAQ:IKT) and CureVac (NASDAQ:CVAC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inhibikase Therapeutics presently has a consensus price target of $5.40, indicating a potential upside of 162.14%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has a net margin of 199.92% compared to Inhibikase Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Inhibikase Therapeutics had 8 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 0 mentions for CureVac. Inhibikase Therapeutics' average media sentiment score of 1.10 beat CureVac's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Positive
CureVac	Neutral

CureVac has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,046.08	-$48.26M	-$0.43	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Inhibikase Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

CureVac beats Inhibikase Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

5.8% of Evotec shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Evotec currently has a consensus target price of $7.00, suggesting a potential upside of 227.10%. Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 162.14%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Inhibikase Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A
Inhibikase Therapeutics	$260K	1,046.08	-$48.26M	-$0.43	N/A

Evotec has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Inhibikase Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

In the previous week, Evotec and Evotec both had 8 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Evotec's score of 0.20 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inhibikase Therapeutics beats Evotec on 7 of the 13 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Inhibikase Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eton Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Eton Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 9.30%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 162.14%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Eton Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	12.85	-$4.60M	-$0.07	N/A
Inhibikase Therapeutics	$260K	1,046.08	-$48.26M	-$0.43	N/A

In the previous week, Inhibikase Therapeutics had 6 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 2 mentions for Eton Pharmaceuticals. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Eton Pharmaceuticals' score of 0.97 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inhibikase Therapeutics beats Eton Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Avalo Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Avalo Therapeutics. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 3 mentions for Avalo Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Avalo Therapeutics' score of 0.65 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibikase Therapeutics' return on equity of -41.31% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Inhibikase Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Inhibikase Therapeutics has higher revenue and earnings than Avalo Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,046.08	-$48.26M	-$0.43	N/A
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A

Inhibikase Therapeutics currently has a consensus target price of $5.40, suggesting a potential upside of 162.14%. Avalo Therapeutics has a consensus target price of $45.80, suggesting a potential upside of 148.64%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Inhibikase Therapeutics beats Avalo Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Kura Oncology?

Inhibikase Therapeutics (NASDAQ:IKT) and Kura Oncology (NASDAQ:KURA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Inhibikase Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Inhibikase Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Inhibikase Therapeutics' return on equity of -41.31% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Kura Oncology	-411.19%	-141.95%	-43.28%

Inhibikase Therapeutics has higher earnings, but lower revenue than Kura Oncology. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,046.08	-$48.26M	-$0.43	N/A
Kura Oncology	$67.48M	14.79	-$278.67M	-$3.35	N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 162.14%. Kura Oncology has a consensus price target of $25.46, suggesting a potential upside of 126.53%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 8 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.10 beat Kura Oncology's score of 1.07 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inhibikase Therapeutics beats Kura Oncology on 12 of the 16 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$258.78M	$563.31M	$4.39B	$12.44B
Dividend Yield	N/A	N/A	30.61%	8.42%
P/E Ratio	-4.79	N/A	23.66	24.38
Price / Sales	1,046.08	395.57	147.41	91.89
Price / Cash	N/A	N/A	165.47	59.36
Price / Book	0.90	2.84	12.86	6.33
Net Income	-$48.26M	-$81.71M	$118.20M	$331.02M
7 Day Performance	-0.48%	-3.69%	-0.84%	-0.33%
1 Month Performance	23.35%	18.94%	-2.90%	-1.29%
1 Year Performance	N/A	-78.43%	11.36%	21.30%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	2.3152 of 5 stars	$2.06 +5.1%	$5.40 +162.1%	N/A	$258.78M	$260K	N/A	6	News Coverage Positive News Analyst Upgrade Gap Up High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
EVO Evotec	3.3698 of 5 stars	$2.92 +0.7%	$7.00 +139.7%	-48.1%	$1.03B	$891.97M	N/A	4,553	News Coverage Analyst Downgrade Gap Down
ETON Eton Pharmaceuticals	2.5853 of 5 stars	$38.02 +1.4%	$41.00 +7.8%	+158.0%	$1.03B	$79.95M	N/A	20
AVTX Avalo Therapeutics	2.7849 of 5 stars	$19.96 +5.9%	$45.80 +129.5%	+275.9%	$990.34M	$60K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. CVAC, EVO, ETON, AVTX, and KURA

How does Inhibikase Therapeutics compare to CureVac?

Summary

How does Inhibikase Therapeutics compare to Evotec?

Summary

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Avalo Therapeutics?

Summary

How does Inhibikase Therapeutics compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. CVAC, EVO, ETON, AVTX, and KURA

How does Inhibikase Therapeutics compare to CureVac?

Do institutionals & insiders have more ownership in IKT or CVAC?

Do analysts rate IKT or CVAC?

Is IKT or CVAC more profitable?

Does the media favor IKT or CVAC?

Which has stronger valuation and earnings, IKT or CVAC?

Which has more volatility and risk, IKT or CVAC?

Summary

How does Inhibikase Therapeutics compare to Evotec?

Do institutionals & insiders believe in EVO or IKT?

Do analysts prefer EVO or IKT?

Which has stronger earnings and valuation, EVO or IKT?

Which has more volatility & risk, EVO or IKT?

Is EVO or IKT more profitable?

Does the media refer more to EVO or IKT?

Summary

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Is ETON or IKT more profitable?

Do insiders & institutionals have more ownership in ETON or IKT?

Which has more risk & volatility, ETON or IKT?

Do analysts recommend ETON or IKT?

Which has preferable valuation & earnings, ETON or IKT?

Does the media refer more to ETON or IKT?

Summary

How does Inhibikase Therapeutics compare to Avalo Therapeutics?

Do insiders and institutionals have more ownership in IKT or AVTX?

Does the media prefer IKT or AVTX?

Is IKT or AVTX more profitable?

Which has more risk & volatility, IKT or AVTX?

Which has better earnings & valuation, IKT or AVTX?

Do analysts prefer IKT or AVTX?

Summary

How does Inhibikase Therapeutics compare to Kura Oncology?

Which has more volatility & risk, IKT or KURA?

Is IKT or KURA more profitable?

Which has preferable valuation & earnings, IKT or KURA?

Do insiders & institutionals hold more shares of IKT or KURA?

Do analysts rate IKT or KURA?

Does the media prefer IKT or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools